Patient adherence remains one of the greatest challenges in the treatment of chronic conditions like asthma and COPD. Traditional oral medications often suffer from poor compliance due to slow onset or complicated dosing schedules. Nasal mucosa delivery devices solve this by offering a "user-friendly" interface that fits easily into a patient's daily routine. The portability and ease of use associated with these devices empower patients to self-administer their treatments in home-care settings, significantly reducing the burden on hospital resources and improving long-term health outcomes.

The Nasal Mucosa Drug Supply Device Market is seeing a shift toward "Connected Care" platforms. By 2026, roughly 18% of new devices in the pipeline will incorporate IoT-enabled sensors that track usage and provide digital feedback to both patients and clinicians. This technological integration is particularly vital for managing chronic obstructive pulmonary disease (COPD), which is currently the fastest-growing application segment. By providing real-time data on dosing history, these smart devices help prevent over-medication and ensure that patients stay within their prescribed therapeutic window, ultimately reducing the frequency of emergency room visits and acute flare-ups.